Salvage Immunotherapy With Pembrolizumab in Patients Hospitalized for Life-Threatening Complications of NSCLC - Université Paris-Est-Créteil-Val-de-Marne Access content directly
Journal Articles JTO Clinical and Research Reports Year : 2021

Salvage Immunotherapy With Pembrolizumab in Patients Hospitalized for Life-Threatening Complications of NSCLC

Abstract

Introduction: It is not known whether patients with NSCLC who are hospitalized because of cancer-related complications are liable to benefit from salvage immunotherapy. Methods: This is a multicenter observational study including five centers, which involve all patients with advanced-stage NSCLC exhibiting a level of programmed death-ligand 1 (PD-L1) greater than or equal to 1%, having been hospitalized because of complications attributed to the evolution of the NSCLC, and having started pembrolizumab treatment during their hospitalization because of a risk of clinical deterioration in the short term. The analysis measured overall survival (OS) and the rate of discharge to home at 3 months. Results: The study included 33 patients, including 28 (85%) with metastatic NSCLC and 27 (82%) under first-line treatment. The main causes of hospitalization were deterioration of the general condition (52%), acute respiratory failure (18%), and an uncontrolled infection owing to the tumor (15%). A total of 20 patients (60%) had a performance status greater than or equal to 2 and 15 (45%) were under oxygen therapy. A total of 29 patients (88%) had a PD-L1 greater than or equal to 50%. Five patients (15%) started pembrolizumab in the intensive care unit. The median OS was 4.3 months (95% confidence interval [CI]: 0.9-not reached), and the 6-month and 1-year OS rates were 41.5% (95% CI: 27.5%-62.6%) and 32.6% (95% CI: 19.0%-55.9%), respectively. The home discharge rate at 3 months was 39% (95% CI: 23%-58%). Conclusions: Even when initiated in patients hospitalized for a life-threatening clinical deterioration, pembrolizumab seems to prolong the survival of certain patients with high PD-L1 NSCLC. Prospective, controlled data are necessary to confirm these results.

Domains

Cancer
Fichier principal
Vignette du fichier
PIIS2666364321000060.pdf (787.53 Ko) Télécharger le fichier
Origin Publisher files allowed on an open archive

Dates and versions

hal-04142800 , version 1 (27-06-2023)

Identifiers

Cite

Ferréol Roborel de Climens, Christos Chouaid, Claire Poulet, Vincent Leroy, Luc Stoven, et al.. Salvage Immunotherapy With Pembrolizumab in Patients Hospitalized for Life-Threatening Complications of NSCLC. JTO Clinical and Research Reports, 2021, 2 (5), pp.100147. ⟨10.1016/j.jtocrr.2021.100147⟩. ⟨hal-04142800⟩
10 View
7 Download

Altmetric

Share

Gmail Mastodon Facebook X LinkedIn More